Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Depreciation & Amortization (CF) (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $818216.0 as the latest value for Q1 2023.

  • Quarterly Depreciation & Amortization (CF) rose 41.97% to $818216.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $818216.0 through Dec 2023, down 70.66% year-over-year, with the annual reading at $2.8 million for FY2022, 29.79% up from the prior year.
  • Depreciation & Amortization (CF) for Q1 2023 was $818216.0 at Marker Therapeutics, up from $813110.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $819883.0 in Q3 2022, with the low at $10514.0 in Q1 2019.
  • Average Depreciation & Amortization (CF) over 5 years is $373357.0, with a median of $502743.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 1325.61% in 2021, then rose 9.35% in 2022.
  • Over 5 years, Depreciation & Amortization (CF) stood at $34215.0 in 2019, then skyrocketed by 522.29% to $212916.0 in 2020, then skyrocketed by 165.12% to $564488.0 in 2021, then skyrocketed by 44.04% to $813110.0 in 2022, then rose by 0.63% to $818216.0 in 2023.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $818216.0, $813110.0, and $819883.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.